A significant reduction in OHSS risk was reported in letrozole-treated patients compared to standard ovarian stimulation protocols with GnRH-a or GnRH-ant co-treatment (1 RCT; OR 0. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.